Comparative Pharmacology
Head-to-head clinical analysis: SPRX 3 versus WILPO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPRX 3 versus WILPO.
SPRX-3 vs WILPO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective sigma-2 receptor ligand; induces mitochondrial dysfunction and endoplasmic reticulum stress leading to apoptosis in cancer cells. Also modulates autophagy.
Wilpo (setmelanotide) is a melanocortin 4 receptor (MC4R) agonist that activates the MC4R pathway to reduce appetite and increase energy expenditure.
Not established; investigational drug. No approved standard adult dose available.
WILPO is not a known or approved drug. No standard dosing information available.
None Documented
None Documented
Terminal elimination half-life: 12 ± 3 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life of 12 hours (range 10-14 h). Steady-state achieved after 2-3 days. Requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (70% unchanged, 15% as glucuronide conjugate); biliary/fecal (10%); other (5%).
Primarily renal (unchanged: 60%, glucuronide conjugate: 20%), biliary/fecal: 15%, other: 5%.
Category C
Category C
Unknown
Unknown